ASCO® Annual Meeting 2022

Precision Oncology Now: Enhancing patient care with integrated clinical applications that are powered by multimodal data

Learn to empower your practice and research program through Tempus’ comprehensive portfolio of NGS offerings. Discover how one of the world’s largest cancer platforms accelerates discovery, provides personalized treatment options, and precisely matches patients to clinical trials.

Join the Tempus team at booth #5063 directly following the session for a live Q&A with the presenters, Dr. James Chen and Dr. Calvin Chao.

Genetic ancestry differences in tumor mutation and expression in early and average onset colorectal cancer

Used genetic ancestry instead of race/ethnicity classes to provide a more quantitative and precise profile of shared genetic background that can underlie biological race differences in cancer etiology and outcomes

Paired tumor/normal sequencing reduces apparent racial differences in tumor mutational burden (TMB)

The use of xT tumor/normal match reduced apparent discrepancy in TMB levels between racial groups, particularly for Black and Asian patients

Real world data enables large-scale assessment of WHO CNS5 glioma classification

Researchers analyzed a de-identified dataset of CNS tumors and found that reclassifying according to the new WHO classification system resulted in more accurate prognostic stratification than the original diagnosis

Dual tissue and plasma testing improves detection of actionable variants in patients with solid cancers

Performing liquid biopsy in addition to tissue based testing identifies more patients with clinically actionable variants

Operational Metrics for the ELAINE II study Combining a Traditional Approach with a Just-in-Time Model

By combining TIME trial and traditional enrollment models clinical trials may recruit more patients and reach full enrollment faster

Clinical RNA-sequencing improves the detection of actionable fusions over DNA-sequencing alone

In the largest fusion analysis of its kind Tempus reviewed a real-world data set of 77,400 patient records for improvement in clinically actionable fusion detection due to the inclusion of RNA sequencing; The inclusion of RNA sequencing improves fusion detection vs DNA alone

Comparative Analysis of the Targetable Landscape in KRAS-mutated and wild-type Pancreatic Adenocarcinoma

Natural Language Processing-Optimized Case Selection for RWE Studies

Comparative analysis of microsatellite instability-high (MSI-H) BRAF V600E–mutated versus MSI-H BRAF wild type colorectal cancers (CRC), including tumor microenvironment (TME), associated genomic alterations, and immuno-metabolomic biomarkers

Genomic landscape of SMARCA4-deficient lung tumors by clinical RNA sequencing

Impact of RAS mutations on immunologic characteristics of the tumor microenvironment (TME) in patients with microsatellite instability-high (MSI-H) or mismatch-repair deficient (dMMR) colorectal cancer (CRC)

Prevalence of high tumor mutational burden (TMB-H) and microsatellite instability-high (MSI-H) status in neuroendocrine neoplasms.

An analysis of EHR records to determine treatment patterns of women with advanced TNBC